...
search icon
inkt-img

Mink Therapeutics Inc, Common Stock

INKT

NAQ

$7.7

+$0.2

(2.67%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$28.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.18K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.14
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.56 L
$13.79 H
$7.7

About Mink Therapeutics Inc, Common Stock

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINKTSectorS&P500
1-Week Return6.06%3.64%6.36%
1-Month Return-10.15%-5.42%-5.32%
3-Month Return-12.89%-6.89%-8.86%
6-Month Return8.65%-7.54%-5.61%
1-Year Return-11.62%-1.81%8.61%
3-Year Return-68.57%2.1%27.58%
5-Year Return-93.58%35.25%90.38%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue--2.70B--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue55.06K28.36B30.95B204.62K-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":91.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(55.06K)(28.36B)(28.24B)(204.62K)-[{"date":"2020-12-31","value":-5506000,"profit":false},{"date":"2021-12-31","value":-2835859100000,"profit":false},{"date":"2022-12-31","value":-2824453500000,"profit":false},{"date":"2023-12-31","value":-20461700,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin--(1044.26%)--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1044.26,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses10.80M18.61M30.95M22.92M10.65B[{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":0.17,"profit":true},{"date":"2022-12-31","value":0.29,"profit":true},{"date":"2023-12-31","value":0.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(14.64M)(28.36M)(30.95M)(22.92M)(10.65M)[{"date":"2020-12-31","value":-1463718600,"profit":false},{"date":"2021-12-31","value":-2835859100,"profit":false},{"date":"2022-12-31","value":-3094927800,"profit":false},{"date":"2023-12-31","value":-2292110500,"profit":false},{"date":"2024-12-31","value":-1065023900,"profit":false}]
Total Non-Operating Income/Expense(4.04M)(4.29M)3.21M1.02M(134.56K)[{"date":"2020-12-31","value":-125.88,"profit":false},{"date":"2021-12-31","value":-133.46,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.76,"profit":true},{"date":"2024-12-31","value":-4.19,"profit":false}]
Pre-Tax Income(16.24M)(30.21M)(27.99M)(22.46M)(10.78B)[{"date":"2020-12-31","value":-1623889800,"profit":false},{"date":"2021-12-31","value":-3021277000,"profit":false},{"date":"2022-12-31","value":-2799121200,"profit":false},{"date":"2023-12-31","value":-2245785900,"profit":false},{"date":"2024-12-31","value":-1078480200000,"profit":false}]
Income Taxes(560.38K)(7.10M)(3.21M)3.00-[{"date":"2020-12-31","value":-18679366.67,"profit":false},{"date":"2021-12-31","value":-236625366.67,"profit":false},{"date":"2022-12-31","value":-107046300,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(15.68M)(23.11M)(24.78M)(22.46M)-[{"date":"2020-12-31","value":-1567851700,"profit":false},{"date":"2021-12-31","value":-2311400900,"profit":false},{"date":"2022-12-31","value":-2477982300,"profit":false},{"date":"2023-12-31","value":-2245786200,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(16.24M)(30.21M)(27.99M)(24.77M)(10.78M)[{"date":"2020-12-31","value":-1623889800,"profit":false},{"date":"2021-12-31","value":-3021277000,"profit":false},{"date":"2022-12-31","value":-2799121200,"profit":false},{"date":"2023-12-31","value":-2476900100,"profit":false},{"date":"2024-12-31","value":-1078480200,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(15.68M)(23.11M)(24.78M)(22.46M)(10.78B)[{"date":"2020-12-31","value":-1567851700,"profit":false},{"date":"2021-12-31","value":-2311400900,"profit":false},{"date":"2022-12-31","value":-2477982300,"profit":false},{"date":"2023-12-31","value":-2245785900,"profit":false},{"date":"2024-12-31","value":-1078480200000,"profit":false}]
EPS (Diluted)(0.70)(1.19)(0.83)(0.66)(1.30)[{"date":"2020-12-31","value":-70.44,"profit":false},{"date":"2021-12-31","value":-119.06,"profit":false},{"date":"2022-12-31","value":-83,"profit":false},{"date":"2023-12-31","value":-66,"profit":false},{"date":"2024-12-31","value":-130.27,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INKT
Cash Ratio 0.66
Current Ratio 0.72

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INKT
ROA (LTM) -137.35%
ROE (LTM) -1238.98%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INKT
Debt Ratio Lower is generally better. Negative is bad. 4.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -3.42

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INKT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 10.05
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Mink Therapeutics Inc share price today?

Mink Therapeutics Inc (INKT) share price today is $7.7

Can Indians buy Mink Therapeutics Inc shares?

Yes, Indians can buy shares of Mink Therapeutics Inc (INKT) on Vested. To buy Mink Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INKT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mink Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Mink Therapeutics Inc (INKT) via the Vested app. You can start investing in Mink Therapeutics Inc (INKT) with a minimum investment of $1.

How to invest in Mink Therapeutics Inc shares from India?

You can invest in shares of Mink Therapeutics Inc (INKT) via Vested in three simple steps:

  • Click on Sign Up or Invest in INKT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mink Therapeutics Inc shares
What is Mink Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Mink Therapeutics Inc (INKT) is $13.79. The 52-week low price of Mink Therapeutics Inc (INKT) is $4.56.

What is Mink Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mink Therapeutics Inc (INKT) is 10.05

What is the Market Cap of Mink Therapeutics Inc?

The market capitalization of Mink Therapeutics Inc (INKT) is $28.80M

What is Mink Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Mink Therapeutics Inc is INKT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top